This trial was a randomized , two-armed , non-inferiority phase 3 comparison of CapeOX ( capecitabine 1000 mg/m2 twice daily on days 1-14 and oxaliplatin 130 mg/m2 on day 1 ) versus SOX ( S-1 40 mg/m2 twice daily on days 1-14 and oxaliplatin 130 mg/m2 on day 1 ) .